Hepatic Metabolic Zonation Collapse in Chronic Liver Injury: Mechanisms, Clinical Relevance, and Emerging Therapeutic Strategies

Abstract

Hepatic metabolic zonation, the spatial compartmentalization of metabolic functions within the liver lobule, is fundamental to hepatic physiology. Chronic liver injury disrupts this intricate organization, leading to zonation collapse and profound metabolic dysregulation. This review synthesizes current evidence on the mechanisms driving zonation collapse, its clinical manifestations, diagnostic considerations, and implications for therapeutic strategies. We discuss recent advances, emerging therapies, and guideline-based recommendations, providing clinicians and researchers with a comprehensive perspective on this critical aspect of liver pathology.

Introduction

The liver's remarkable metabolic versatility is underpinned by the concept of zonation distinct functional zones along the porto-central axis of the hepatic lobule. This compartmentalization allows hepatocytes to specialize in processes such as gluconeogenesis, ureagenesis, and xenobiotic metabolism in response to gradients of oxygen, nutrients, and hormones. Chronic liver injury, irrespective of etiology, disrupts hepatic architecture and the molecular circuits governing zonation, culminating in metabolic collapse. Understanding the pathophysiology, clinical implications, and evolving management strategies for hepatic metabolic zonation collapse is essential for optimizing outcomes in chronic liver disease (CLD).

Epidemiology / Disease Burden

Chronic liver injury, primarily driven by viral hepatitis, alcohol-related liver disease, and nonalcoholic fatty liver disease (NAFLD), remains a global health concern, affecting over 1.5 billion individuals worldwide. The rising incidence of metabolic-associated fatty liver disease (MAFLD) and the persistence of viral hepatitis in low-resource settings exacerbate disease burden. Zonation collapse is increasingly recognized as an early and critical event in the progression to cirrhosis and hepatic decompensation, contributing to the high morbidity and mortality associated with chronic liver disorders.

Pathophysiology

Hepatic metabolic zonation is orchestrated by dynamic gradients of oxygen, hormones (notably insulin and glucagon), morphogens (such as Wnt/β-catenin and Hedgehog), and extracellular matrix components. In chronic liver injury, persistent inflammation, fibrogenesis, and architectural distortion disrupt these gradients. Hepatocyte dedifferentiation, loss of Wnt/β-catenin signaling, and aberrant activation of hepatic stellate cells lead to a breakdown of metabolic compartmentalization. The resulting collapse impairs essential functions: perivenous urea cycle activity diminishes, periportal gluconeogenesis and β-oxidation falter, and xenobiotic clearance is compromised. Animal models and human transcriptomic analyses corroborate these changes, highlighting profound metabolic reprogramming in diseased livers.

Risk Factors

Key risk factors for zonation collapse mirror those for chronic liver injury: chronic viral hepatitis (HBV, HCV), excessive alcohol intake, metabolic syndrome, obesity, type 2 diabetes, genetic predispositions (such as PNPLA3 polymorphisms), and exposure to hepatotoxins. Repeated episodes of hepatic inflammation, oxidative stress, and steatosis amplify the risk by promoting fibrosis and architectural distortion. Additionally, age, male sex, and comorbidities (e.g., cardiovascular disease) may modulate vulnerability to metabolic zonation collapse.

Clinical Features

The clinical manifestations of hepatic metabolic zonation collapse are insidious and often overlap with those of chronic liver disease. Patients may present with fatigue, jaundice, pruritus, coagulopathy, and signs of hepatic encephalopathy. Laboratory findings reflect global hepatocellular dysfunction: rising serum ammonia (impaired urea cycle), hypoglycemia (defective gluconeogenesis), dyslipidemia, and altered drug metabolism. The loss of zonation-specific enzyme activity can explain atypical drug responses and heightened vulnerability to metabolic crises in advanced disease stages.

Diagnosis

Diagnosis of zonation collapse is challenging due to the lack of direct clinical markers. Histological analysis remains the gold standard, with immunohistochemistry for zone-specific enzymes (e.g., glutamine synthetase for perivenous hepatocytes, carbamoyl phosphate synthetase for periportal cells) providing evidence of disrupted zonation. Advanced imaging, such as multiparametric MRI and positron emission tomography (PET) with metabolic tracers, offers noninvasive insights. Transcriptomic and proteomic profiling from liver biopsies can reveal loss of zonal gene expression signatures. Routine liver function tests, while nonspecific, may suggest metabolic derangements consistent with zonation collapse.

Treatment & Management

Management hinges on addressing the underlying etiology of liver injury antiviral therapy for hepatitis, abstinence from alcohol, weight reduction and metabolic control in NAFLD/MAFLD, and avoidance of hepatotoxins. Supportive measures include optimizing nutrition, managing complications (ascites, varices, encephalopathy), and individualized pharmacotherapy, considering altered drug metabolism. Liver transplantation remains definitive for end-stage disease with irreversible zonation collapse. Multidisciplinary care and regular monitoring are pivotal for patients at risk of progression.

Recent Advances / Emerging Therapies

Recent research has illuminated mechanisms of zonation maintenance and collapse, unveiling novel therapeutic targets. Pharmacological modulation of Wnt/β-catenin signaling shows promise in preclinical models, potentially restoring zonal metabolic functions. Antifibrotic agents, such as inhibitors of transforming growth factor-β (TGF-β) and platelet-derived growth factor (PDGF), are under investigation for their ability to preserve hepatic architecture. Single-cell transcriptomics is enabling precise mapping of zonation disruptions, guiding personalized interventions. Regenerative medicine approaches including stem cell therapy and bioengineered liver tissues offer hope for reversing zonation collapse in advanced disease.

Guideline Recommendations

Major hepatology societies (AASLD, EASL, APASL) emphasize early identification and management of chronic liver injury to prevent irreversible architectural changes and metabolic collapse. Guidelines advocate for routine surveillance in high-risk populations, prompt antiviral or metabolic intervention, and consideration of liver biopsy or advanced imaging in cases of diagnostic uncertainty. Emerging consensus highlights the need for research into noninvasive biomarkers and targeted therapies addressing zonation disruption.

Conclusion

Hepatic metabolic zonation collapse is a pivotal event in the progression of chronic liver injury, driving metabolic dysfunction and clinical deterioration. Advances in understanding the molecular mechanisms of zonation maintenance and collapse are paving the way for innovative diagnostic and therapeutic approaches. Clinicians should remain vigilant for metabolic complications in chronic liver disease and integrate guideline-based management with emerging evidence to optimize patient outcomes. Future research focused on restoring zonal architecture and function holds the potential to transform the care of patients with chronic liver injury.